


## The “Flip” Side

For investors who can short . . . or own deteriorating longs

01/29/26

Charts highlighted: BMI, XYL, VLTO, VC, QCOM, QRVO, SWKS, SONY, LOGI, EXTR, RACE, FSS, HOG, CVI, NEU, VITL, SNY, BHC, PODD, ABT, CNMD, STVN, GIS, KHC, CPB, REYN, PVH, KTB, BFAM, FOUR, PYPL, KLAR, TYL, GDDY, PAYX, KD, BR, CDW, RBRK, BSY, HPQ, ROP, HUBS, ADBE, ADP, SAP, PLTR, DUOL, PAYC, NOW, MNDY, CVLT, AGYS, DSGX, RBLX, TRMB, FIS, BTNX, DOCS, HNGE, INTA, TTD, TOST, IOT, WAY, GEN, PHR, SDGR, SPOT, NFLX, MMYT, PINS, HUM, ADUS, EHC, HIMS, FLUT, PLNT, BKE, MA, WRLD, AFRM, VOIN, and HOOD.



**Short Shots** is a collection of technically vulnerable charts culled from the “Negative Inflecting” and “Tippy” columns within our *Weekly Compass* report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons **Short Shots** can also be a great source of ideas for investors interested in short-selling candidates.






David P. Nicoski, CMT  
612-682-1900  
dave@vermilioncap.com



Joe W. Jasper, CFA  
612-682-1900  
joe@vermilioncap.com



Ross LaDuke, CMT  
612-482-8442  
Ross@vermilioncap.com


















































































































## HNGE-USA

Hinge Health, Inc. Class A \$37.65

Price Chg: 0.00 % Chg: 0.00 Avg Vol: 1,135,727 Yield: 0 % MktCap: 2,964 MM

Operates as a platform that provides musculoskeletal

P/E LTM P/E NTM 23.4

US dollars



## INTA-USA


Intapp, Inc. \$36.50



Price Chg: 0.00 % Chg: 0.00 Avg Vol: 658,317 Yield: 0 % MktCap: 2,990 MM



Provides cloud-based software solutions for the pr


P/E LTM P/E NTM 27.8


US dollars











































This page intentionally left blank.

David P. Nicoski, CMT  
952-922-7502  
dave@vermilioncap.com

Joe W. Jasper, CFA  
952-922-7501  
joe@vermilioncap.com

Ross, LaDuke, CMT  
952-922-7506  
Ross@vermilioncap.com

920 2nd Avenue S; Suite 1225 • Minneapolis, MN 55402 • 952-922-7500 • [www.vermilioncap.com](http://www.vermilioncap.com)

**Disclaimer:** The information contained herein is privileged, confidential and protected from disclosure. Any unauthorized disclosure, distribution, dissemination or copying of this material or any attachment is strictly prohibited; such information, whether derived from Vermilion Research or from any oral or written communication by way of opinion, advice, or otherwise with a principal of the company is not warranted in any manner whatsoever, is for the use of our customers only and may be obtained from internal and external research sources considered to be reliable. It is not necessarily complete and its accuracy is not guaranteed by Vermilion Research, its operating entity or the principals therein. Neither the information nor any opinion expressed constitutes a solicitation for the purchase of any future or security referred to in Vermilion research publications. Principals of Vermilion Research may or may not hold, or be short of, securities discussed herein, or of any other securities, at any time. The foregoing also expressly applies to any trial subscription. EU disclaimer: The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.

